Lee Fairlie to Spike Glycoprotein, Coronavirus
This is a "connection" page, showing publications Lee Fairlie has written about Spike Glycoprotein, Coronavirus.
Connection Strength
0,380
-
Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial. Hum Vaccin Immunother. 2024 Dec 31; 20(1):2425147.
Score: 0,226
-
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial. Hum Vaccin Immunother. 2025 Dec; 21(1):2450120.
Score: 0,057
-
Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19. Viruses. 2023 02 06; 15(2).
Score: 0,050
-
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial. Lancet HIV. 2022 05; 9(5):e309-e322.
Score: 0,047